Focus Financial Network Inc. Sells 312 Shares of Exact Sciences Co. (NASDAQ:EXAS)

Focus Financial Network Inc. reduced its stake in shares of Exact Sciences Co. (NASDAQ:EXAS) by 8.0% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 3,608 shares of the medical research company’s stock after selling 312 shares during the period. Focus Financial Network Inc.’s holdings in Exact Sciences were worth $203,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Geode Capital Management LLC grew its holdings in Exact Sciences by 0.3% during the third quarter. Geode Capital Management LLC now owns 3,105,970 shares of the medical research company’s stock worth $211,104,000 after buying an additional 7,873 shares in the last quarter. Champlain Investment Partners LLC grew its stake in shares of Exact Sciences by 10.9% in the 3rd quarter. Champlain Investment Partners LLC now owns 2,494,480 shares of the medical research company’s stock worth $169,924,000 after acquiring an additional 245,980 shares in the last quarter. Bellevue Group AG raised its holdings in shares of Exact Sciences by 25.1% in the third quarter. Bellevue Group AG now owns 1,449,465 shares of the medical research company’s stock valued at $98,738,000 after purchasing an additional 290,585 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its position in shares of Exact Sciences by 3.6% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,292,090 shares of the medical research company’s stock valued at $88,017,000 after purchasing an additional 45,015 shares in the last quarter. Finally, Groupama Asset Managment bought a new position in shares of Exact Sciences during the third quarter valued at about $821,000. 88.82% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. Piper Sandler decreased their price objective on shares of Exact Sciences from $85.00 to $75.00 and set an “overweight” rating for the company in a research note on Monday, November 11th. The Goldman Sachs Group decreased their price target on Exact Sciences from $75.00 to $65.00 and set a “buy” rating for the company in a research report on Wednesday, November 6th. Canaccord Genuity Group reduced their price objective on Exact Sciences from $95.00 to $75.00 and set a “buy” rating for the company in a research note on Wednesday, November 6th. Barclays initiated coverage on Exact Sciences in a research note on Thursday, January 23rd. They set an “overweight” rating and a $70.00 target price on the stock. Finally, Benchmark reissued a “buy” rating and issued a $65.00 price target on shares of Exact Sciences in a report on Monday, January 13th. One equities research analyst has rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. Based on data from MarketBeat, Exact Sciences presently has a consensus rating of “Moderate Buy” and an average target price of $72.76.

Exact Sciences Stock Performance

NASDAQ:EXAS opened at $49.31 on Friday. The business’s fifty day moving average is $56.15 and its 200 day moving average is $60.09. The firm has a market cap of $9.13 billion, a price-to-earnings ratio of -42.14 and a beta of 1.24. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.93 and a current ratio of 2.12. Exact Sciences Co. has a 52-week low of $40.62 and a 52-week high of $79.62.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.